MedTrace Logo

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

NCT00558571 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2014-08-07

Study results available
· View outcomes & findings →

Summary

Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

BI 10773 low dose

DRUG

placebo to BI 10773

DRUG

BI 10773 medium dose

DRUG

BI 10773 high dose

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00558571 on ClinicalTrials.gov